Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
l�ll
Clinical trials in severe sepsis with drotrecogin alfa (activated) Laterre PFCrit Care 2007[]; 11 Suppl 5 (Suppl 5): S5Drotecogin alfa (activated; DrotAA) was approved in 2001 by the US Food and Drug Administration for the treatment of patients with severe sepsis who are at high risk for death. The European Agency for the Evaluation of Medical Products also recommended that DrotAA could be administered to patients with severe sepsis and multiple organ dysfunction when added to the best standard care. Following the initial publication of the PROWESS (Protein C Worldwide Evaluation in Severe Sepsis) findings, multiple subgroup analyses supported the need for additional studies to explore the various hypotheses raised by this study. This review discusses all large clinical trials exploring the efficacy and safety of DrotAA and proposes recommendations for the use of DrotAA in severe sepsis.|*Clinical Trials as Topic[MESH]|APACHE[MESH]|Adult[MESH]|Anti-Infective Agents/adverse effects/*therapeutic use[MESH]|Child[MESH]|Clinical Trials, Phase I as Topic[MESH]|Clinical Trials, Phase II as Topic[MESH]|Clinical Trials, Phase III as Topic[MESH]|Clinical Trials, Phase IV as Topic[MESH]|Drug Administration Routes[MESH]|Drug Administration Schedule[MESH]|Hemorrhage/chemically induced[MESH]|Humans[MESH]|Multicenter Studies as Topic[MESH]|Product Surveillance, Postmarketing[MESH]|Protein C/adverse effects/*therapeutic use[MESH]|Recombinant Proteins/adverse effects/blood/therapeutic use[MESH]|Research Design[MESH]|Sepsis/blood/*drug therapy/mortality[MESH]|Survival Rate[MESH] |